Clinical Trial Goal
To find out:
- The highest dose of AB8939 that's safe to give
- If AB8939 is safe and works well to treat AML that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have AML that has relapsed or is refractory
- Do not have acute promyelocytic leukemia
- Are not eligible for an autologous (your own cells) or an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Are not eligible for standard treatment options
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
AB8939 is a small molecule synthesized tubulin inhibitor.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You'll get:
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You'll get:
- AB8939 – Given as intravenous (IV) infusions . The dose you'll get depends on when you start the trial and how safe it has been
- Venetoclax – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for about 2 months.
The Food and Drug Administration (FDA) has not yet approved AB8939.
Locations
MD Anderson Cancer CenterNOT_YET_RECRUITING
Houston, Texas
Sponsors
lead: AB Science
